title: Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma.
abstract: OBJECTIVE
  To compare the clinicopathological characteristics of human epidermal growth factor receptor 2 (HER2)-positive and HER2-negative Barrett's adenocarcinoma in Japan.
  
  
  METHODS
  We performed immunohistochemical analysis of HER2 in 30 samples taken from patients with Barrett's adenocarcinoma and dual color in situ hybridization in cases showing 2+ reactions. We compared the clinicopathological characteristics of HER2-positive and HER2-negative patients.
  
  
  RESULTS
  HER2 positivity was identified in 8 (27%) carcinoma samples. We found that HER2 expression was associated with p53 overexpression (100% vs 52.6% in pT1 tumor; 100% vs 54.5% in all stage tumor, P < 0.05) and protruding lesions at the early disease stage. There was no association between the mucin phenotype of the carcinomas and prognosis. HER2 expression and low clinical stage were unexpectedly different between Barrett's adenocarcinoma patients and gastric cancer patients, but the macroscopic features may be associated with earlier diagnosis in these patients.
  
  
  CONCLUSIONS
  Our results suggest that HER2-positive Barrett's adenocarcinomas are associated with p53 overexpression and lesion protrusion at the early disease stage.
authors.affiliation: Department of Pathology, Okayama University Hospital, Okayama 700-8558, Japan. takehiro@md.okayama-u.ac.jp
authors.forename: Takehiro
authors.initials: T
authors.lastname: Tanaka
authors.forename: Atsushi
authors.initials: A
authors.lastname: Fujimura
authors.forename: Koichi
authors.initials: K
authors.lastname: Ichimura
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yanai
authors.forename: Yasuharu
authors.initials: Y
authors.lastname: Sato
authors.forename: Katsuyohi
authors.initials: K
authors.lastname: Takata
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Okada
authors.forename: Seiji
authors.initials: S
authors.lastname: Kawano
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Tanabe
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yoshino
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry* / Q000235:genetics / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001471:Barrett Esophagus / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics; D016009:Chi-Square Distribution; D055088:Early Detection of Cancer; D004938:Esophageal Neoplasms / Q000737:chemistry* / Q000235:genetics / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007564:Japan; D008297:Male; D008875:Middle Aged; D009077:Mucins / Q000032:analysis; D009367:Neoplasm Staging; D010641:Phenotype; D011230:Precancerous Conditions / Q000737:chemistry* / Q000235:genetics / Q000473:pathology; D011237:Predictive Value of Tests; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000032:analysis; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; D009077:Mucins; D018719:Erb-b2 Receptor Tyrosine Kinases; D016159:Tumor Suppressor Protein p53; C495901:TP53 protein, human; C508053:ERBB2 protein, human